The Therapy of Large Endometrioma

University Hospital, Lille62 enrolled

Overview

Endometrioma's prevalence is between 23 and 55%. It causes pelvic pain, decrease fertility and ovarian reserve. Currently, there's no recommendation about large endometrioma's treatment and there's no information on the best treatment to limit recurrences, preserve fertility and ovarian reserve. In Lille university hospital, simple laparoscopic drainage associated with hormonal therapy is practiced to reduce the risk of cystectomy. This protocol will be evaluated with an observational and prospective study, including women of childbearing age having endometrioma measuring 6 cm or above. The aim of this study is to assess if cyst drainage associated with GnRH agonist, could decrease endometrioma recurrences, deleterious effect on ovarian reserve and evaluate impact on anti-mullerian hormone

Study Type

OBSERVATIONAL

Enrollment

Conditions

Endometrioma Endometriosis Ovary

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Endometrioma size ≥ 6cm determined by MRI or ultrasonography * Women with isolated endometrioma or other extraovarian endometriosis: peritoneal, infiltrating endometriotic lesions and adenomyosis. * Cyst single or bilateral Exclusion Criteria: * Cyst with radiographic or macroscopic in laparoscopy atypia * Pregnancy * Patient with contraindication to GnRH agonist (Enantone® 3,75 mg et Decapeptyl® 3 mg) * Patient with contraindication to laparoscopy * Patient with contraindication to general anesthesia * Subject refusing to participate in the study

Outcomes

Primary Outcomes

Rate of Recurrence of cyst ≥ 3 cm determined by MRI or pelvic ultrasonography (US)

Time frame: at 3 months

Secondary Outcomes

The impact of the ovarian reserve postoperative

Compare the dosages of anti-mullerian hormone (AMH) preoperative and postoperative at 3 months

Time frame: at 3 months

The number of re-operation

Time frame: at 4 months